ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys.
Abstract readLetterComment
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Weighing the evidence on cabozantinib and thrombotic risk.Blood advances · 2026Article
- Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study.EClinicalMedicine · 2025Article
- Unmasking the Rare but Lethal Cardiac Complications of Immune Checkpoint Inhibitor Therapy: A Review of Mechanisms, Risk Factors, and Management Strategies.Current treatment options in oncology · 2025Review
- Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors.JACC. CardioOncology · 2024Article
- Article
- Reply to S. Rossi et al and P. Palassin et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
7 authors.
Pascale PalassinPascale Palassin, PharmD, PhD, and Jean-Luc Faillie, MD, PhD, Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France; Cyrille Coustal, MD, Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France; Xavier Quantin, MD, PhD, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France; Delphine Topart, MD, Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; François Roubille, MD, PhD, Department of Cardiology, Montpellier University Hospital, Montpellier, France; and Alexandre T.J. Maria, MD, PhD, Internal Medicine & Immuno-Oncology (MedIO), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.ORCID 0000-0003-2717-9437
Jean-Luc FailliePascale Palassin, PharmD, PhD, and Jean-Luc Faillie, MD, PhD, Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France; Cyrille Coustal, MD, Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France; Xavier Quantin, MD, PhD, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France; Delphine Topart, MD, Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; François Roubille, MD, PhD, Department of Cardiology, Montpellier University Hospital, Montpellier, France; and Alexandre T.J. Maria, MD, PhD, Internal Medicine & Immuno-Oncology (MedIO), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.
Cyrille CoustalPascale Palassin, PharmD, PhD, and Jean-Luc Faillie, MD, PhD, Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France; Cyrille Coustal, MD, Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France; Xavier Quantin, MD, PhD, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France; Delphine Topart, MD, Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; François Roubille, MD, PhD, Department of Cardiology, Montpellier University Hospital, Montpellier, France; and Alexandre T.J. Maria, MD, PhD, Internal Medicine & Immuno-Oncology (MedIO), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.ORCID 0000-0002-7317-2933
Xavier QuantinPascale Palassin, PharmD, PhD, and Jean-Luc Faillie, MD, PhD, Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France; Cyrille Coustal, MD, Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France; Xavier Quantin, MD, PhD, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France; Delphine Topart, MD, Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; François Roubille, MD, PhD, Department of Cardiology, Montpellier University Hospital, Montpellier, France; and Alexandre T.J. Maria, MD, PhD, Internal Medicine & Immuno-Oncology (MedIO), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.
Delphine TopartPascale Palassin, PharmD, PhD, and Jean-Luc Faillie, MD, PhD, Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France; Cyrille Coustal, MD, Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France; Xavier Quantin, MD, PhD, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France; Delphine Topart, MD, Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; François Roubille, MD, PhD, Department of Cardiology, Montpellier University Hospital, Montpellier, France; and Alexandre T.J. Maria, MD, PhD, Internal Medicine & Immuno-Oncology (MedIO), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.ORCID 0000-0002-1145-8039
François RoubillePascale Palassin, PharmD, PhD, and Jean-Luc Faillie, MD, PhD, Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France; Cyrille Coustal, MD, Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France; Xavier Quantin, MD, PhD, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France; Delphine Topart, MD, Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; François Roubille, MD, PhD, Department of Cardiology, Montpellier University Hospital, Montpellier, France; and Alexandre T.J. Maria, MD, PhD, Internal Medicine & Immuno-Oncology (MedIO), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.ORCID 0000-0002-5288-9687
Alexandre T J MariaPascale Palassin, PharmD, PhD, and Jean-Luc Faillie, MD, PhD, Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France; Cyrille Coustal, MD, Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France; Xavier Quantin, MD, PhD, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France; Delphine Topart, MD, Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; François Roubille, MD, PhD, Department of Cardiology, Montpellier University Hospital, Montpellier, France; and Alexandre T.J. Maria, MD, PhD, Internal Medicine & Immuno-Oncology (MedIO), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.ORCID 0000-0002-0868-5804
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsAdverse Drug Reaction Reporting SystemsHeartHumansImmune Checkpoint InhibitorsPharmacovigilanceAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors
Identifiers
PMID
36318740What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.